logo-loader

Shares of vTv Therapeutics skyrocket on Alzheimer's Phase 3 trial results

Published: 14:01 10 May 2018 EDT

Pills
Results suggest azeliragon offers significant benefit to some patients with mild Alzheimer’s disease

Shares in vTv Therapeutics Inc.(NASDAQ:VTVT) are rocketing after the clinical stage biopharmaceutical group revealed welcome news about a Phase 3 clinical study involving Alzheimer’s disease.

The company has announced that despite not meeting its co-primary endpoints, the data from Part A of the company’s Phase 3 STEADFAST study of its medication azeliragon in people with mild Alzheimer’s disease suggests that the drug offers a significant benefit relative to a placebo in some patients after a year.

vTv Therapeutics climbed 22% to US$2.08 in afternoon trade Thursday.

The patients with Alzheimer’s who saw the most improvement took lower doses of azeliragon, with peak blood plasma concentrations of the drug of less than 7.5ng/mL.

“We are encouraged by the positive improvements in cognitive and functional outcomes relative to placebo based upon low azeliragon concentration levels,” said Steve Holcombe, chief executive of vTv Therapeutics.

Post its analysis and using data from prior trials, the company will submit a revised statistical analysis plan to the Food and Drug Administration to start the part B phase of its study. It expects to announce another set of results from its trials in June.

Coniagas Battery Metals secures new key ground with focus on...

Coniagas Battery Metals (TSX-V:COS) CEO Frank Basa joined Steve Darling from Proactive to announce the company's strategic acquisition of key ground near SOQUEM’s Cardinal Property, located 80 km southeast of Chibougamau, Quebec. This acquisition underscores Coniagas’ commitment to capitalizing...

19 minutes ago